Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant BL-B01D1 plus Almonertinib in EGFR-mutated NSCLC
NCT06951464Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab brengitecan in non-small cell lung cancer (NSCLC), sponsored by Sichuan University. Started Jun 2025; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06951464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951464.